News
PharmAust (ASX: PAA) has changed its name to Neurizon Therapeutics - NUZ (ASX: NUZ).
Below are the previous articles from PharmAust (ASX: PAA):
RELATED STOCKHEAD STORIES
Health & Biotech
PharmAust makes progress in the quarter as it lays the foundation for commercialisation
Q-Wrapz
Q-Wrapz: Oriel Morrison interviews Roger Aston, executive chairman of PharmAust Ltd (ASX:PAA)
Health & Biotech
PharmAust’s pill significantly protects against COVID-19 virus
Health & Biotech
PharmAust files for patent on lead drug monepantel to fight viral diseases
Health & Biotech
PharmAust signs deal and broadens Monepantel’s scope on antiviral activities
News
Market highlights and 5 ASX small caps to watch on Monday
Health & Biotech
PharmAust flags good news on key stability test for Monepantel treatment
Health & Biotech
PharmAust achieves successful Phase II trials on monepantel for canine cancer, shares jump
News
Market Highlights and 5 ASX Small Caps to watch on Monday
News
ScoPo’s Powerplays: Mental health takes centre stage; Actinogen to progress Alzheimer’s study
Health & Biotech
PharmAust set to commence Phase I trial of Monepantel in patients with motor neurone disease
News
Market highlights and 5 ASX small caps to watch on Wednesday
Health & Biotech
PharmAust calls on experienced exec in push to commercialise its drug for canine cancer
Health & Biotech
Budget review: Here’s what ASX biotech players thought of the ‘patent box’
Health & Biotech
PharmAust sees numerous potential catalysts for next 12 months
Health & Biotech
PharmAust passes critical milestone in Phase II study of Monepantel, sets eyes on Phase III
Tech
